X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/ex-novartis-pituitary-senior-medical-director-chiasma-svp-jumps-to-recordati-rare-disease
https://www.globenewswire.com/news-release/2021/06/28/2254272/0/en/Chiasma-Announces-Submission-of-Marketing-Authorization-Application-for-MYCAPSSA-to-the-European-Medicines-Agency.html
https://www.globenewswire.com/news-release/2021/06/15/2247089/0/en/Amryt-Pharma-Announces-Filing-of-Preliminary-Registration-Statement-on-Form-F-4-in-Connection-with-Its-Proposed-Acquisition-of-Chiasma-Inc.html
https://www.globenewswire.com/fr/news-release/2021/05/20/2233291/0/en/Chiasma-to-Present-Encore-and-New-Data-from-MPOWERED-Phase-3-Trial-at-Upcoming-e-ECE-and-AACE-Virtual-Conferences.html
https://www.globenewswire.com/news-release/2021/05/20/2233291/0/en/Chiasma-to-Present-Encore-and-New-Data-from-MPOWERED-Phase-3-Trial-at-Upcoming-e-ECE-and-AACE-Virtual-Conferences.html
https://www.globenewswire.com/news-release/2021/03/20/2196502/0/en/Chiasma-Presents-New-Positive-Data-for-MYCAPSSA-from-Phase-3-Trial-MPOWERED-for-the-Maintenance-Treatment-of-Acromegaly-at-ENDO-2021.html
http://www.globenewswire.com/news-release/2021/03/22/2197191/0/en/Chiasma-Presents-Long-Term-Safety-and-Efficacy-Data-from-the-Open-Label-Extension-Study-of-its-CHIASMA-OPTIMAL-Phase-3-Trial-Evaluating-MYCAPSSA-in-Patients-with-Acromegaly-at-ENDO.html
https://www.biospace.com/article/chiasma-s-octreotide-capsules-could-be-answer-to-acromegaly-patients-treatment-burdens/
https://www.globenewswire.com/news-release/2020/08/31/2086104/0/en/Chiasma-Announces-U-S-Commercial-Launch-and-Availability-of-MYCAPSSA-the-First-and-Only-Oral-Somatostatin-Analog-for-Patients-with-Acromegaly.html
https://www.globenewswire.com/news-release/2020/08/17/2079187/0/en/Chiasma-Announces-Publication-of-Pivotal-Data-from-the-Phase-3-CHIASMA-OPTIMAL-Clinical-Trial-in-the-Journal-of-Clinical-Endocrinology-Metabolism.html
Market Place
Share 
